In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Galapagos licenses Phase II RA candidate to Abbott; AbbVie takes over and deal expands to Crohn's disease; deal ends

Executive Summary

Galapagos NV has licensed Abbott Laboratories Inc. exclusive global rights to develop and commercialize GLPG0634, a highly selective Janus kinase (JAK) inhibitor in Phase II for rheumatoid arthritis and other autoimmune diseases.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies